menu search

COPHF / Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD

Creso Pharma psychedelics subsidiary Halucenex lodges CTA to test efficacy of psilocybin on treatment-resistant PTSD
Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) psychedelics subsidiary Halucenex Life Sciences Inc has lodged a Clinical Trial Authorisation (CTA) with Health Canada for a planned phase II clinical trial to test the efficacy of psilocybin on treatment-resistant Post Traumatic Stress Disorder (PTSD). The proposed phase II clinical trial is designed to be a single-arm, open-lab trial that will ultimately determine the feasibility of future trials of psilocybin in this indication. Read More
Posted: Jan 24 2022, 21:40
Author Name: Proactive Investors
Views: 110872

COPHF News  

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

By Proactive Investors
July 18, 2022

Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) (Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF), Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)) subsidiary Halucenex Life more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

By Proactive Investors
February 7, 2022

Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF)'s wholly-owned, Canadian-based psychedelics subsidiary Halucenex Life Sciences Inc. has been included on a li more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

By Benzinga
February 4, 2022

Australian Creso Pharma To Enter US CBD Market Via $21M Acquisition Of Sierra Sage Herbs

Cannabis company Creso Pharma Limited (ASX: CPH) (OTC: COPHF) (FRA:1X8) is entering the US CBD market, following a purchase agreement to acquire Color more_horizontal

Creso Pharma pushes into US CBD market with revenue-generating acquisition

By Proactive Investors
February 2, 2022

Creso Pharma pushes into US CBD market with revenue-generating acquisition

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has entered the US CBD market. The company has executed a Membership Interest Purchase Agreement to acquire Co more_horizontal


Search within

Pages Search Results: